Welcome to Markets Desk, here's what's moving the tape this afternoon.
Boeing is back in the headlines with a fighter jet contract worth twenty billion dollars, adding to last year's F-47 Air Force award. This is a significant vote of confidence in Boeing's defense division at a time when the company has faced serious operational and reputational headwinds on the commercial side. Defense revenue is increasingly carrying the load.
Shifting to trade and energy policy, President Trump is turning up the heat on South Korea over the Alaska liquefied natural gas project, warning Seoul that a failure to sign on will result in steeper tariffs. South Korea has been cautious about committing to the investment, and Trump's comments signal that LNG deal-making is now explicitly tied to broader trade leverage in the region.
In biotech, CSL and Alentis Therapeutics have announced a global collaboration to develop lixudebart, a potential first-in-class treatment targeting claudin-one for rare kidney and liver diseases. The deal is valued at up to one point six billion dollars and gives CSL a meaningful foothold in the rare disease space, where pricing power and exclusivity can drive long-term margin strength.
That's the tape. Markets Desk, signing off the floor.
